Cosciens Biopharma Inc. (ET8)

Overview

COSCIENS Biopharma Inc. stands as a focal entity in the biopharmaceutical sector, with its core operations rooted in the research, development, and global commercialization of therapeutic and diagnostic solutions. The company, based in Toronto, Canada, boasts a significant international presence, extending its services across several key regions including Canada, Switzerland, Ireland, Denmark, Germany, the United States, among others. Initially recognized as Aeterna Zentaris Inc., the company underwent a rebranding process to COSCIENS Biopharma Inc. in August 2024, marking a pivotal evolution in its corporate identity. Since its inception in 1990, COSCIENS has dedicated itself to addressing complex medical conditions through innovative biopharmaceutical applications, concentrating its efforts in the realms of endocrinology and oncology.

Products and Services

Macrilen (macimorelin): This flagship product of COSCIENS Biopharma stands out as an orally administered peptidomimetic ghrelin receptor agonist. Designed to bind with the GHSR-1a, Macrilen is instrumental in stimulating the secretion of growth hormone, catering to the diagnostic needs of both adult and childhood-onset growth hormone deficiency. Its applications span further into other endocrinology and oncology indications, showcasing its versatility and critical relevance in the medical community.

AEZS-150: Operating in the preclinical trial phase, AEZS-150 is being developed as a delayed clearance parathyroid hormone fusion polypeptide. This innovative therapeutic candidate is aimed at treating chronic hypoparathyroidism, embodiments a promising frontier in endocrine disorder management.

AEZS-130: Another pivotal component of COSCIENS Biopharma’s product pipeline, AEZS-130, is at the preclinical trial stage, targeting the treatment of amyotrophic lateral sclerosis (ALS). This initiative underscores the company’s commitment to resolving neurodegenerative diseases through advanced biopharmaceutical interventions.

Collaborative Efforts and Agreements: COSCIENS Biopharma has forged strategic alliances to broaden its impact and reach within the biopharmaceutical industry. Notable collaborations include a license and research agreement with the University of Wuerzburg, focused on developing AIM biologicals for addressing neuromyelitis optica spectrum disorder and exploring potential treatments for Parkinson’s disease. Additionally, partnerships with Consilient Health Ltd. and NK MEDITECH Ltd. pave the way for the development and commercialization of Macrilen, further amplified by a distribution alliance with Er-Kim Pharmaceuticals Bulgaria Eood for Macrilen’s commercialization. The alliance with The University of Sheffield in the UK is tailored towards the development and commercialization of parathyroid hormone fusion polypeptides, specifically targeting chronic hypoparathyroidism, illustrating COSCIENS Biopharma’s collaborative approach in advancing healthcare solutions.